Vernalis PLC Vernalis Results of Annual General Meeting (2977Z)

TIDMVER

RNS Number : 2977Z

Vernalis PLC

14 December 2017

14 December 2017

LSE: VER

Vernalis Results of Annual General Meeting

Resolutions

Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.

All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.

 
                                         For (including discretionary 
 Resolution                                         votes)*                   Against*        Withheld 
-------------------------------------  -------------------------------  -------------------  ---------- 
 Ordinary Resolutions (requires 50% majority) 
------------------------------------------------------------------------------------------------------- 
 1. That the audited accounts 
  and related reports of the 
  directors and auditors for 
  the 12 month period ended                                  (>99.99                 (<0.01 
  30 June 2017 be received                 461,562,562          %)         1,314       %)        370 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
 2. That the remuneration 
  report contained within the 
  report and accounts for the 
  12 month period ended 30                                   (>99.25                 (<0.75 
  June 2017 be approved                    458,122,758          %)       3,439,440     %)       2,048 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
 3. That Dr Fellner be re-elected                            (<99.58                 (>0.42 
  as a director                            457,720,835          %)       1,932,577     %)     1,910,834 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
 4. That Ms Ferguson be re-elected                           (<99.27                 (>0.73 
  as a director                            458,150,220          %)       3,383,604     %)      30,422 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
 5. That Mr Garland be re-elected                            (>99.67                 (<0.33 
  as a director                            460,030,263          %)       1,503,561     %)      30,422 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
 6. That PricewaterhouseCoopers 
  LLP be reappointed auditors 
  and the directors be authorised                            (<99.59                 (>0.41 
  to determine their remuneration          459,664,328          %)       1,899,230     %)        688 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
 7. That the directors be                                    (>99.66                 (<0.34 
  authorised to allot shares               459,993,972          %)       1,568,601     %)       1,673 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
                              Special Resolutions (requires 75% majority) 
------------------------------------------------------------------------------------------------------- 
 8. That the directors be 
  authorised to disapply pre-emption                         (>99.64                 (<0.36 
  rights                                   459,912,679          %)       1,649,048     %)       2,519 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
 9. That the directors be 
  authorised to disapply pre-emption 
  rights in connection with 
  an acquisition or specified                                (<99.24                 (>0.76 
  capital investment                       458,032,320          %)       3,529,263     %)       2,663 
-------------------------------------  ------------------  -----------  ----------  -------  ---------- 
 

*NB: A vote withheld is not a vote in law and, is not counted in the calculation of the votes for or against a resolution. Therefore, the percentage of votes cast excludes withheld votes

On 14 December 2017, there were 526,819,624 Vernalis plc ordinary shares in issue. Shareholders are entitled to one vote per share held.

The full text of each resolution passed at the Annual General Meeting held earlier today, Thursday 14 December 2017, is set out in the Notice of Annual General Meeting which is available for viewing on the Company's website at www.vernalis.com.

-- ends --

Enquiries:

 
 Vernalis:                                       [phone] 
 Ian Garland, Chief Executive Officer 
  David Mackney, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated Adviser 
  and Joint Broker):                             [phone] 
 Henry Fitzgerald-O'Connor 
  Emma Gabriel 
 Shore Capital (Joint Broker):                    [phone] 
 Mark Percy 
  Toby Gibbs 
 FTI Consulting:                                 [phone] 
 Ben Atwell 
  Simon Conway 
  Stephanie Cuthbert 
 Stern Investor Relations:                        [phone] 
 Stephanie Ascher 
  Jane Urheim 
 

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra(R) XR, targeting the US prescription cough-cold market; Moxatag(R) , a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last ten years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, and Tris.

For further information about Vernalis, please visit www.vernalis.com.

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its NCE pipeline, the Company's ability to successfully commercialise its cough-cold products and Moxatag(R) through its own salesforce, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Tuzistra(R) XR, Moxatag(R) , frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGLFFLIFALVLID

(END) Dow Jones Newswires

December 14, 2017 08:15 ET (13:15 GMT)